 |
|
Adding to the confusion in more than just the name
Jacob George
Clin Mol Hepatol. 2023;29(4):973-976. Published online 2023 Sep 18 DOI: https://doi.org/10.3350/cmh.2023.0367
|
|
Citations to this article as recorded by
 Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
Diabetes & Metabolism.2024; 50(1): 101506. CrossRef Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC
Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka
European Journal of Gastroenterology & Hepatology.2024; 36(4): 430. CrossRef Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice
Paul N Brennan, Oliver D Tavabie, Wenhao Li, Thomas Marjot, Lynsey Corless, Jonathan A Fallowfield, Helen Jarvis, Dina Mansour, Stuart McPherson, William Rosenberg, Karen Rockell, Jeremy Tomlinson, Andrew Yeoman, Emmanuel A Tsochatzis, John F Dillon, Will
The Lancet Gastroenterology & Hepatology.2024;[Epub] CrossRef Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon
Clinical and Molecular Hepatology.2023; 30(1): 118. CrossRef
|